Pediatric rheumatology

Trajectories of Physical Function in Canadian Children With Juvenile Idiopathic Arthritis

Arthritis Care Res (Hoboken)Published Prospective cohort study

Authors' conclusion

Most children with JIA in this cohort had mild to moderate functional impairments at diagnosis that resolved in one to two years, but one in three followed trajectories with mild persisting impairments.

Study context

Population
Children newly diagnosed with juvenile idiopathic arthritis (JIA) enrolled in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry 2017–2024 with parent-reported Kids Disability Screen (KDS, 0–10) scores from ≥2 visits7,351 KDS scores
Participants
940 children
Outcome
Trajectories of physical function (KDS, 0 = no disability to 10 = severe disability)
Methodological detailsregistry-based, latent class trajectory analysis, classification trees
  • Registry-based
  • Latent class trajectory analysis
  • Classification trees

Main finding

As reported in the abstract

KDS trajectories (latent class trajectory analysis (LCTA), five trajectories)

Little measurable impairment

38%

Impairments resolving in one to two years (two trajectories)

24%

Persisting mild impairments (two trajectories)

38%

Observational data: associations, not effects.

Further findings

Baseline KDS by JIA category

Highest: RF-positive polyarthritis, mean (SD 3.1)
4.9
Lowest: psoriatic arthritis, mean (SD 2.5)
2.4
Mean scores improved within the first year in all JIA categories

Median time to KDS = 0

Weeks

Overall median
36
Systemic arthritis
13
Undifferentiated arthritis
73

Baseline KDS ≥1.5 to detect persisting mild impairment trajectories

Sensitivity
0.79
Specificity
0.48

Original publication

Trajectories of Physical Function in Canadian Children With Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). Published 14 May 2026. doi:10.1002/acr.80039

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.